Anti-TNF biologic therapy does not increase postoperative morbidity in pediatric Crohn's patients
Author / Expert
Amy L. Lightner, Nicholas P. McKenna, Ahmad Alsughayer, Edward V. Loftus, Laura E. Raffals, William A. Faubion, Christopher Moir
Topic overview
Abstract
Introduction
Limited knowledge exists as to what impact preoperative biologic therapy has on postoperative complications in pediatric patients undergoing abdominal surgery for Crohn's disease (CD). Therefore, we sought to determine the 30-day postoperative infectious complication rate among pediatric CD patients who received biologic therapy within 12 weeks of an abdominal operation.
Methods
A retrospective chart review was performed on pediatric (
Comments